Daiwa Securities Group’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-92
| Closed | -$3K | – | 1386 |
|
|
2025
Q4 | $3K | Buy |
+92
| New | +$2.86K | ﹤0.01% | 1284 |
|
|
2024
Q4 | – | Sell |
-13
| Closed | – | – | 1321 |
|
|
2024
Q3 | $0 | Hold |
13
| – | – | ﹤0.01% | 1324 |
|
|
2024
Q2 | $0 | Hold |
13
| – | – | ﹤0.01% | 1355 |
|
|
2024
Q1 | $1K | Hold |
13
| – | – | ﹤0.01% | 1304 |
|
|
2023
Q4 | $3K | Hold |
13
| – | – | ﹤0.01% | 1251 |
|
|
2023
Q3 | $2K | Hold |
13
| – | – | ﹤0.01% | 1223 |
|
|
2023
Q2 | $2K | Hold |
13
| – | – | ﹤0.01% | 1244 |
|
|
2023
Q1 | $2K | Hold |
13
| – | – | ﹤0.01% | 1223 |
|
|
2022
Q4 | $2K | Hold |
13
| – | – | ﹤0.01% | 1235 |
|
|
2022
Q3 | $2K | Hold |
13
| – | – | ﹤0.01% | 1245 |
|
|
2022
Q2 | $2K | Hold |
13
| – | – | ﹤0.01% | 1251 |
|
|
2022
Q1 | $2K | Hold |
13
| – | – | ﹤0.01% | 1267 |
|
|
2021
Q4 | $4K | Hold |
13
| – | – | ﹤0.01% | 1225 |
|
|
2021
Q3 | $3K | Buy |
13
+7
| +117% | +$1.85K | ﹤0.01% | 1225 |
|
|
2021
Q2 | $1K | Hold |
6
| – | – | ﹤0.01% | 1207 |
|
|
2021
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 1216 |
|
|
2020
Q4 | $1K | Buy |
+6
| New | +$1.3K | ﹤0.01% | 1196 |
|
Daiwa Securities Group's RAPT Position: Q1 2026 in Review
Daiwa Securities Group sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 92 shares — an estimated $3K sold.
Daiwa Securities Group first reported a position in RAPT in Q4 2020 and held it in 17 quarters. The position peaked at $4K in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Daiwa Securities Group reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 92 RAPT Therapeutics shares in Q1 2026, an estimated $3K.
- Daiwa Securities Group first reported a position in RAPT Therapeutics in Q4 2020 and held it in 17 quarters.
- Daiwa Securities Group's RAPT Therapeutics position peaked at $4K in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.